The aim of this cohort study was to estimate the risk of clinical acute liver injury among users of oral antifungals identified in the general population of the General Practice Research Database in UK. Methods The cohort included 69 830 patients, 20-79 years old, free of liver and systemic disease, who had received at least one prescription for either oral fluconazole, griseofulvin, itraconazole, ketoconazole, or terbinafine between 1991 and 1996. Results Sixteen cases of acute liver injury were identified and validated. Ten cases occurred during nonuse of oral antifungals with a background rate of 0.6 per 100 000 person-months (95% confidence interval 0.3,1.1). Five cases occurred during current use of oral antifungals. Two were using ketoconazole, another two itraconazole, and one terbinafine. Incidence rates of acute liver injury were 134.1 per 100 000 person-months (36.8,488.0) for ketoconazole, 10.4 (2.9-38.1) for itraconazole, and 2.5 (0.4,13.9) for terbinafine. The remaining case was associated with past use of fluconazole. Ketoconazole was the antifungal associated with the highest relative risk, 228.0 (95% confidence interval 33.9,933.0), when compared with the risk among nonusers, followed by itraconazole and terbinafine with relative risks of 17.7 (2.6,72.6) and 4.2 (0.2,24.9), respectively. Conclusions Ketoconazole and itraconazole were the two oral antifungal associated with a marked increase of clinical acute liver injury. The risk associated with ketoconazole should be taken into account when prescribing it as initial treatment for uncomplicated fungal infections.
hepatic injury associated with ketoconazole than with Introduction other systemic antifungals [2, 3] . Some authors have estimated the incidence to lie between one per 1000 and Oral antifungals have been associated with different types of acute liver injury in a number of case reports and in 3000 patients, after taking into account the effect of underreporting in spontaneous monitoring systems [4, 5] . several retrospective series. Most of the available data relate to ketoconazole. Transient asymptomatic changes
In a randomized clinical trial, patients with onychomycosis treated with ketoconazole had a threefold increased risk in liver function tests can appear in 0.5% to 10% of patients treated with oral antifungals [1] . Clinical liver of developing hepatitis compared with patients treated with griseofulvin [6] . Several cases of liver injury have injury appears to be less frequent, although the vast majority of data come from cases reported to national been reported in association with griseofulvin [7, 8] , itraconazole [9, 10] , and terbinafine [11] [12] [13] [14] , and most pharmacovigilance systems.
Published reviews have reported a higher incidence of cases related with fluconazole have occurred in severely immunodepressed patients [15] [16] [17] [18] [19] [20] . In a recent post- on drug-induced acute liver injury have been published using the GPRD resource [24] . These studies were able acute liver injury was defined as a person presenting with to quantify the risk of clinical liver injury associated with symptoms suggestive of liver disorder (nausea, vomiting, suspected hepatotoxic drugs.
abdominal pain and/or jaundice) referred to a specialist or admitted to hospital, and who was free of the exclusion Study cohort criteria. In addition, the following biochemical test results, based on an international consensus meeting, were a The study cohort comprised people aged 20-79 years requisite as part of the case definition of liver injury [25]: who had received at least one prescription for either oral an increase of more than two times the upper limit of fluconazole, griseofulvin, itraconazole, ketoconazole, or the normal range in alanine aminotransferase (ALT), or a terbinafine between 1 January 1991 and 30 September combined increase in aspartate aminotransferase (AST), 1996. We excluded subjects if they had a history of liver alkaline phosphatase (APh) and total bilirubin, provided injury in the preceding 5 years. Subjects with a history any was more than twice the upper limit of the respective of any of the following conditions were also excluded: normal range. The liver injury was classified as acute if cancer, liver disease, gallbladder disease, pancreatic disease, the clinical and laboratory signs had lasted less than 6 heart failure, alcohol abuse, HIV infection, rheumatoid months from the date of onset. The type of liver injury arthritis, sarcoidosis, systemic lupus or inflammatory was designated hepatocellular when there was an increase bowel disease. The final study cohort was constituted by more than twice the upper limit of the normal range in 69 830 individuals. We followed these persons from the ALT alone or R≥5, where R is the ratio of serum date of first antifungal drug prescription until the earliest activity of ALT over serum activity of APh. Liver injury occurrence of a code for liver injury (Table 1) , one of was designated cholestatic when there was an increase of the exclusion conditions mentioned above, age greater more than twice the upper limit of the normal range in than 80 years, death or the end of the study period.
APh alone or R≤2. Liver injury was designated mixed when 2<R<5.
Case ascertainment

We identified 73 patients with a recorded history
Exposure definition compatible with acute liver injury. We requested from the general practitioners all clinical records related to Person time at risk was aggregated in three different time windows according to use of the study antifungal drugs. these events. Case validation was independently performed by three of the authors (LAGR, BHChS, and AD) Current use encompassed all the days of prescribed treatment plus an additional period of 14 days at the end without knowledge of the exposure status and agreement was reached on all cases after some discussion. A case of of treatment. Past use was defined as the period of 90 days following the time window of current use. case status. Fifty patients did not meet the study case definition and the reasons for exclusion are presented in Finally, the time period starting after past use was defined as nonuse. We also assessed exposure to a number of Table 3 . Most of the patients presented only with minor elevations of LFTs, or had their LFTs' derangement suspected hepatotoxic drugs among the cases [26] .
found through routine monitoring. Thus, 16 individuals met all case definition criteria. Eleven presented with Analysis jaundice and four were admitted to a hospital. All cases recovered from the hepatic injury and none of them Incidence rates of acute liver injury were calculated using as denominator both the number of patients exposed to resulted in a fatal outcome. Table 4 shows the clinical and laboratory features of the 16 cases classified according each individual antifungal drug and the corresponding person-time at risk. Ninety-five percent confidence to their exposure status. Ten cases occurred during nonuse of oral antifungal drugs corresponding to a intervals were computed on the basis of a Poisson distribution of case counts within categories of use. The background rate of 0.6 per 100 000 person-months (95% CI 0.3,1.1). This risk increased considerably with age: Exact program was used to obtain estimates of rate ratios [27] .
0.4 per 100 000 in persons younger than 60 years and 2.8 per 100 000 in older persons. No material difference was observed between males and females (0.8 vs 0.5 per Results 100 000 person-months). Half of the cases among nonusers were exposed to a hepatotoxic drug (Table 4 ). The study cohort of 69 830 subjects received a total of 149 384 prescriptions. There were marked age and sex
Estimates of incidence rate for current use of individual antifungal drugs are presented in Table 5 . Two cases differences among users of the five antifungal drugs with a higher proportion of women and young patients among occurred during current use of ketoconazole and itraconafluconazole and itraconazole users (Table 2 ). These differences were a consequence of varying leading indications: candidiasis for fluconazole, itraconazole and terbinafine users were treated for 1-3 months.
Alcoholism 3
Griseofulvin users were the group with the longest Cholelithiasis 3 duration of treatment with one third of patients taking it
History of liver disorder 2 for a period longer than 3 months.
Infectious mononucleosis 1
We received medical records for 66 patients (90%). In
Computer entry error 1 seven subjects, we did not receive information from the Total 50 GPs, or the data received were insufficient to ascertain *Some of the members of the cohort received more than one antifungal drug during the study period. F=female; M=male; C=cholestatic; H=hepatocellular; M=mixed. †Multiplier of upper limit of normal value of alanine aminotransferase (ALT) and alkaline phosphatase (AP). ‡Pattern of liver injury. §Itraconazole, ketoconazole and terbinafine indicate current exposure to these antifungals. Case with past use had been exposed to fluconazole. zole, respectively, one case with terbinafine, and no cases under everyday circumstances. Because of the low number of detected cases, effect modification by gender or age were found with current use of fluconazole and griseofulvin. All five cases developed during the first month of could not be assessed. Therefore, only crude rates are presented. When compared to the risk in nonusers, the starting antifungal treatment. Ketoconazole presented the greatest absolute risk with an incidence rate of 134 per risk of acute liver injury was markedly increased in users of ketoconazole and itraconazole, and slightly increased 100 000 person-months followed by itraconazole (10.4 per 100 000 person-months) and terbinafine (2.5 per in users of terbinafine. The risk of acute liver injury among ketoconazole users was the greatest with a relative 100 000 person-months). Ketoconazole was the antifungal drug associated with the greatest relative risk compared risk exceeding 200 compared with nonuse. In view of the low background risk of idiopathic symptomatic to the background risk among nonusers (Table 5) , followed by itraconazole and terbinafine.
hepatic injury in the general population, almost 134 extra cases occurred per 100 000 person-months of treatment with ketoconazole. Thus almost 1 in every 500 users of Discussion ketoconazole developed acute liver injury. This is higher than has been estimated in earlier studies with the In this retrospective cohort study, we assessed the risk of acute liver injury to antimycotics in a large population exception of one clinical trial [6] . In a recent review of greater than one per 1000 users) [24] . In the current study, it is highly unlikely that the References results are explained by bias or confounding. Because the complete patient population attended by about 1500
